Original Research Article

Maternal and neonatal characteristics of babies admitted with congenital CNS anomalies in a tertiary hospital in North Central Nigeria

Udochukwu Michael Diala1*, Bose Ozoiza Toma1, Danaan Shilong2, David Danjuma Shwe1, Gyang Bot3, Akinyemi Olugbenga D. Ofakunrin1, Peter Binitie2

1Department of Paediatrics, 2Department of Surgery, University of Jos, Jos, Plateau State, Nigeria
3Department of Surgery, Jos University Teaching Hospital, Jos, Plateau State, Nigeria

Received: 14 April 2018
Accepted: 22 May 2018

*Correspondence:
Dr. Udochukwu Michael Diala,
E-mail: dialaum@yahoo.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: CNS anomalies are an important group of largely preventable congenital anomalies. Knowledge of maternal and neonatal sociodemographic characteristics could identify a pattern of population at risk in order to target preventive interventions.

Methods: This was a 3-year retrospective review of health records of all neonates admitted with CNS anomalies in Jos University Teaching Hospital (JUTH), Jos, central-Nigeria.

Results: Out of a total of 27 neonates with congenital CNS anomalies reviewed, 25 had neural tube defects, 1 hydrocephalos and 1 anencephaly. The peak age group of mothers were 20-29 years (44.4%) and 30-39 years (44.4%). Twenty-two (81.5%) mothers had antenatal care (ANC). No mother booked in the 1st month and only 7 (25.9%) booked in the first trimester. Twenty-four (88.9%) mothers took folic acid during pregnancy. No mother had periconceptional folic acid use. There were 11(40.7%) home births with 14(87.5%) of the 16 hospital births taking place in lower tier health facilities. Twenty-six (96.3%) mothers had vaginal delivery. An obstetric ultrasound scan was reported by one (3.7%) mother and did not detect the anomaly. Five (18.5%) of the mothers had HIV infection. Twenty-six were term with a male: female ratio of 1:1:1. The median age at presentation was 2 (interquartile range 1, 8) days.

Conclusions: Neonates with congenital CNS anomalies in JUTH frequently had mothers aged <35 years who did not receive preventive care before and during delivery. We therefore recommend interventions to improve the efficiency of health care delivery to cater for this gap.

Keywords: Central nervous system anomalies, Maternal sociodemographic

INTRODUCTION

Central nervous system (CNS) congenital anomalies are one of the commonest abnormalities congenital malformations.1-3 They contribute to long-term disability, which may have significant impacts on individuals, families, health-care systems, and societies. Although approximately 50% of all congenital anomalies cannot be linked to a specific cause, 7-8% are as a result of gene mutations or chromosomal defects and 20-25% are due to multifactorial causes.4-6 Folic acid deficiencies especially during the first month of gestation when neurulation takes place has been associated with development of neural tube defects (NTDs), the commonest CNS anomalies. Other factors thought to be associated with CNS anomalies include vitamin B12 deficiency, infections early in pregnancy and exposure to teratogens
(carbamazepine, valproate and clomiphene). It is generally known that dietary intake of folic acid is deficient in most populations especially in low and middle income countries (LMICs). Pre-conceptional use of folic acid and food fortification with folic acid have been reported to reduce the incidence of neural tube defects in some developed countries and has formed part of national recommendations and guidelines. However, a good proportion of women use folic acid after the first month when it is too late to influence the development of NTDs. Awareness of the maternal and neonatal characteristics of congenital anomalies in an area can be useful in the implementation of preventive and control programs. We therefore set out to describe the maternal and neonatal sociodemographic characteristics of neonates admitted with congenital CNS anomalies at the Jos University Teaching Hospital (JUTH), Jos to provide baseline data for further evaluation of possible risk factors.

**METHODS**

This was a retrospective study of all neonates admitted to Jos University Teaching Hospital (JUTH) with congenital CNS anomalies between October 2013 and September 2016. JUTH is a 500 bed-space tertiary level public hospital in Jos, North-Central Nigeria which serves as a referral center for many states in North-central Nigeria. The neonatal unit has 30 bed spaces and neonates with surgical conditions are usually co-managed with other specialties.

All neonates admitted with CNS congenital anomalies into the neonatal unit were identified from the admission registers. Maternal demographic and obstetric data were extracted from the case notes and admission registers. Gestational age was routinely calculated from last menstrual period or new Ballard score. The unit diagnostic protocol includes a CT scan of the brain and spinal cord. Birth defects were classified in line with the ICD 10 version 2016 classification. Data was entered into a Microsoft office Excel sheet and analyzed using SPSS 17.0. Descriptive data were presented in frequency tables.

**RESULTS**

There were 27 neonates admitted with congenital CNS anomalies during the period under review. Twenty-five (92.8%) had neural tube defects, 1 hydrocephalus and 1 anencephaly (Table 1).

**Table 1: Types and frequencies of CNS anomalies in studied neonates.**

| Type of CNS anomaly      | Frequency (n=27) | Percentage (%) |
|-------------------------|------------------|----------------|
| Neural tube defects      | 25               | 92.8           |
| Hydrocephalus alone      | 1                | 3.7            |
| Anencephaly              | 1                | 3.7            |

Mean maternal age was 28.2±5.9 years with 14 mothers (44.4%) aged between 20 and 29 years and 14 mothers (44.4%) aged 30-39 years. Only one mother was aged ≥40 years. Twenty-two (81.5%) of the mothers attended antenatal care (ANC). None of the mothers booked in the 1st month and only 7 (25.9%) booked in the first trimester. Twenty-four (88.9%) mothers took folic acid during pregnancy. None of the mothers had documentation of folic acid use prenatally or during the first month of pregnancy. There were 11 (40.7%) home births with 14 (87.5%) of the 16 hospital births taking place in lower tier health facilities including PHCs. Vaginal deliveries accounted for 26 (96.3%) of the mode of delivery. An obstetric ultrasound scan was reported by one (3.7%) mother, but the scan did not detect the anomaly. Five (18.5%) of the mothers had HIV infection. All HIV mothers were on cotrimoxazole (CTX) and highly active anti-retroviral therapy (HAART) (Table 2).

**Table 2: Maternal sociodemographic characteristics of neonates with CNS anomalies.**

| Variable                        | Frequency (n=27) | Percentage (%) |
|---------------------------------|------------------|----------------|
| Mean Age of Mothers             | 28.2±5.9         |                |
| **Age group of mothers**        |                  |                |
| 20-29 years                     | 12               | 44.4           |
| 30-39 years                     | 12               | 44.4           |
| ≥40 years                       | 1                | 4.0            |
| Missing                         | 2                | 7.4            |
| **ANC booking**                 |                  |                |
| Unbooked                        | 5                | 18.5           |
| <1 month                        | 0                | 0              |
| 1-3 months                      | 7                | 25.9           |
| 4-6 months                      | 13               | 48.1           |
| >6 months                       | 2                | 7.4            |
| **Folic acid use in pregnancy** |                  |                |
| Yes                             | 24               | 88.9           |
| No                              | 3                | 11.1           |
| **Mode of delivery**            |                  |                |
| Vaginal delivery                | 26               | 96.3           |
| Caesarean section               | 1                | 3.7            |
| **Place of birth**              |                  |                |
| Tertiary Hospital               | 2                | 7.4            |
| Public secondary hospitals      | 5                | 18.5           |
| Private hospitals               | 7                | 25.9           |
| Primary health care centers     | 2                | 7.4            |
| Home                            | 11               | 40.7           |
| **HIV infection**               |                  |                |
| Yes*                            | 5                | 18.5           |
| No                              | 21               | 81.5           |

*All the mothers were on HAART (Zidovudine (AZT)/Tenofovir (TDF), lamivudine (3TC) and Nevirapine (NVP)/Efavirenz (EFZ)) and on co-trimoxazole (CTX).

With regards to the neonates, there were 14 males with a male: female ratio of 1:1. The median age at
presentation was 2 (interquartile range 1, 8) days. The peak gestational age of the neonates was 38-40 weeks (26, 96.3%) and 19 (70.4%) had admitting weights of 2500-4000g. There was a history of birth asphyxia in 4 (14.8%) babies (Table 3).

Table 3: Characteristics of neonates with CNS malformations.

| Variable                  | Frequency (n=27) | Percentage (%) |
|---------------------------|------------------|----------------|
| Median age in days (range) | 2 (1.8)          |                |
| Sex                       |                  |                |
| Male                      | 14               | 51.9           |
| Female                    | 13               | 48.1           |
| Gestational age (in weeks)|                  |                |
| 36-37                     | 1                | 3.7            |
| 38-40                     | 26               | 96.3           |
| Weight on admission (g)   |                  |                |
| <2500                     | 7                | 25.9           |
| 2500-4000                 | 19               | 70.37          |
| >4000                     | 1                | 3.7            |
| Presence of asphyxia      |                  |                |
| Yes                       | 4                | 14.8           |
| No                        | 23               | 85.2           |

DISCUSSION

Neonates with CNS anomalies in our study were almost entirely term babies with predominantly (70%) normal weights. This proportion of term and low birth weight is similar to a report of 90.9% term births in a study in north-west, Nigeria but higher than 57% delivered at term and 52% being low birth weight reported in another study.18,19 The studied neonates generally presented within the 1st week of life which is much earlier than reported form studies in Lagos where mean age of presentation was 5.6 months.20 In another study, 86% presented after the first month of life.21 The rather early presentation of the studied neonates may stem from the fact that the general public perception was that babies born with these major congenital defects require urgent care and that JUTH serves as the only neurosurgical referral site in the state where patients enjoy subsidized cost of care from the government. This compares favorably with reports from large cities where delay may be underpinned by seeking care in other health facilities and the high cost of health care.

In this study, most mothers with neonates with CNS anomalies were aged <35 years which mirrors the age group of mothers giving birth in the population and depicts simple mass effect and has been similarly reported in other studies.22,23 In one report, maternal age >35 year (and >40 years) was associated with reduced risk for congenital anomalies. This evidence generally challenges previous reports of increased risk of congenital anomalies with increasing maternal age.24,26 Also, it has been argued that the influence of increasing maternal age is mainly seen in chromosomal anomalies such as the trisomies.27 Therefore, since the etiology of NTDs (the main form of CNS anomalies) are largely non-chromosomal, there may be a negligible influence of advanced maternal age. However, Czeizel A reported an increased risk of NTDs with advanced maternal age.25 Factors such as dietary intake of folic acid and other vitamins and socioeconomic status may also account for higher incidence of CNS anomalies in younger women.26

Our study also reported that most of the mothers did not have antenatal care or booked at an age too late to influence development of CNS anomalies. Also, even though a high proportion had folic acid supplementation in pregnancy, it was started at an age too late to prevent CNS anomalies. This is the same pattern seen in other studies.26,28,29 Therefore for preventive interventions to be effective, they have to be targeted at women of child bearing age or the general population. Pre-conceptional folic acid supplementation has been shown to reduce NTDs but requires that the women are knowledgeable about it and that pregnancies are planned. However, this may be impracticable as a high proportion of pregnancies are unplanned and there is prevalent ignorance and poor health seeking behavior among women in LMICs. Therefore, the realistic community based approach to preventing NTDs will be food fortification as exemplified by national programs on fortification of grains with folic acid in Canada and USA.33,34

Also, in our study, a good proportion (5/27) of neonates with CNS anomalies were born to mothers who were HIV infected. This finding raises the question of the possibility of maternal HIV infection being an independent risk factor for NTDs or the possibility of antiretroviral drugs or CTX increasing the risk of NTDs. CTX is a drug with anti-folate effect. Czeizel AE et al, in a case-control study evaluating the teratogenic effect of CTX in Hungarian women reported a significant increase in the incidence of major congenital anomalies mainly congenital heart defects among women who used CTX in pregnancy.32 Another study among HIV pregnant women reported that while single use of ARVs in first trimester was not associated with increased risk of congenital anomalies, the use of ARVs and anti-folate drugs in first trimester was associated with an increased risk of the same.33 Use in pregnancy of anti-folate drugs has also been reported not to increase risk of NTDs.34 However, that study had a small sample size with18 NTDs among cases and 16 NTDs among control.

In spite of the fact that only 18.5% of index pregnancies were unbooked, over 40% had home delivery, none had prenatal ultrasonic diagnosis and only 7.4% were delivered in a tertiary hospital. These underscore, a population with poor health seeking behavior and a weak health system unable to identify and adequately care these high risk pregnancies.
CONCLUSION

Neonates with congenital CNS anomalies are commonly delivered to women younger than 35 years who commence folic acid supplementation when it is too late to prevent these anomalies and often have antenatal care and delivered at home or in health facilities not able to care for these high risk deliveries. Mothers with HIV infection contributed a significant proportion to these anomalies. Therefore, interventions promoting periconceptional folic acid supplementation, early prenatal diagnosis, maternal utilization of health care facilities with an efficient referral system are recommended to prevent and effectively manage CNS anomalies. It will also be worthwhile to further explore the interaction between HIV infection, ARVs and CTX and risk for CNS anomalies.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee (JUTH/DCS/ADM/127/ XIX/6643)

REFERENCES

1. Gillani S, Kazmi NH, Najeeb S, Hussain S, Raza A. Frequencies of congenital anomalies among newborns admitted in nursery of Ayub Teaching Hospital Abbottabad, Pakistan. J Ayub Med Coll Abbottabad. 2011;23(1):117-21.
2. Adeyemo AA, Okolo CM, Omotade OO. Major congenital malformations among paediatric admissions at University College Hospital, Ibadan, Nigeria. Ann Trop Paediatr. 1994;14(1):75-9.
3. Ambe JP, Madziga AG, Akpede GO, Mava Y. Pattern and outcome of congenital malformations in new born babies in a Nigerian teaching hospital. West Afr J Med. 2010;29(1):24-9.
4. Opitz JM, Wilson GN, Barness EG. Abnormalities of blastogenesis, organogenesis, and phenogenesis. Potter’s Pathology of the Fetus and Infant. St. Louis: Mosby. 1997:65-102.
5. Keeling JW, Boyd PA. Congenital abnormalities and the examination of the fetus following prenatal suspicion of congenital abnormality. In: Fetal and Neonatal Pathology. 3rd edition. Springer. 2001:111-52.
6. Lemmens M, van Vugt JG, Willemsen M, van der Voorn P, van Bokhoven H, ten Donkelaar HJ. Causes of congenital malformations In: Donkelaar HJ, Lemmens M, Hori A, eds. Clinical Neuroembryology. 2nd ed. Berlin Heidelberg: Springer;2014:105-64.
7. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med. 1993;86:703-8.
8. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med. 1991;324(10):674-77.
9. Blaw ME, Woody RC. Valproic acid embryopathy? Neurology. 1983;33(2):255.
10. Wilson JG. Environment and Birth Defects. New York: Academic Press;1973.
11. The National Academics of Sciences Engineering Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, Folate, vitamin B12, pantothenic acid, biotin, and choline. In:Washington DC: National Academies Press;1998. Available at: http://www.nap.edu/catalog/6015.html.
12. Czeizel AE, Dudas I, Verczkey A, Banhidy F. Folate deficiency and folic acid supplementation: the prevention of neural-tube defects and congenital heart defects. Nutrients. 2013;5(11):4760-75.
13. De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald B, et al. Reduction in neural-tube defects after folic acid fortification in Canada. New Eng J Med. 2007 Jul 12;357(2):135-42.
14. Wilson RD, Genetics C. Motherisk. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can. 2007;29(12):1003-13.
15. Abdullahi H, Gasim IG, Saeed A, Imam AM, Adam I. Antenatal iron and folic acid supplementation use by pregnant women in Khartoum, Sudan. BMC Research Notes. 2014;7:498.
16. Nilsen RM, Vollset SE, Gjessing HK, Magnus P, Meltzer HM, Haugen M, et al. Patterns and predictors of folic acid supplement use among pregnant women: the Norwegian Mother and Child Cohort Study. Am J clinical nutrition. 2006 Nov 1;84(5):1134-41.
17. World Health Organization. Chapter XVII Congenital malformations, deformations and chromosomal abnormalities (Q00-099). In: International Statistical Classification of Diseases and Related Health Problems 10th Revision. ICD-10 Version:2016: World Health Organization;2016.
18. Fontoura FC, Cardioso MVL. Association between congenital malformation and neonatal and maternal variables in neonatal units of a Northeast Brazilian city. Text Content Nursing. 2014;23(4):907-14.
19. Nuadi DC, Singh S. The prevalence of neural tube defects in north-west Nigeria. Suadi J Health Sci. 2016;5(1):6-10.
20. Adeleye AO, Olowookere KG. Central nervous system congenital anomalies: a prospective neurosurgical observational study from Nigeria. Congenit Anom (Kyoto). 2009;49(4):258-61.
21. Idowu OE, Olawehinmi OS. Surgical congenital central nervous system anomalies in a tropical teaching hospital. Br J Neurosurg. 2012;26(5):726-9.
22. Airede KI. Neural tube defects in the middle belt of Nigeria. J Trop Pediatr. 1992;38(1):27-30.
23. Goetzinger KR, Shanks AL, Odibo AO, Macones GA, Cahill AG. Advanced Maternal Age and the Risk of Major Congenital Anomalies. Am J Perinatol. 2017;34(3):217-22.
24. Baird PA, Sadovnick AD, Yee IM. Maternal age and birth defects: a population study. Lancet. 1991;337(8740):527-30.
25. Czeizel A. Maternal mortality, fetal death, congenital anomalies and infant mortality at an advanced maternal age. Maturitas. 1988;1:73-81.
26. Hollier LM, Levana KJ, Kelly MA, McIntire DD, Cunningham AFG. Maternal age and malformations in singleton births. Obstetrics and Gynecology. 2000;96(1):701-6.
27. Hagen A, Entezami M, Gasiorek-Wiens A, Albig M, Becker R, Knoll U, et al. The impact of first trimester screening and early fetal anomaly scan on invasive testing rates in women with advanced maternal age. Ultraschall in der Medizin-Euro J Ultrasound. 2011 Jun;32(03):302-6.
28. Kim MJ, Kim J, Hwang EH, Song Y, Kim H, Hyun T. Awareness, knowledge, and use of folic acid among non-pregnant Korean women of childbearing age. Nutr Res Pract. 2018;12(1):78-84.
29. Dessie MA, Zeleke EG, Workie SB, Berihun AW. Folic acid usage and associated factors in the prevention of neural tube defects among pregnant women in Ethiopia: cross-sectional study. BMC Pregnancy Childbirth. 2017;17(1):313.
30. Persad VL, Van den Hof MC, Dube JM, Zimmer P. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ. 2002;167(3):241-5.
31. Hamner HC, Tinker SC. Fortification of corn masa flour with folic acid in the United States: an overview of the evidence. Ann N Y Acad Sci. 2014;1312:8-14.
32. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reproductive Toxicology. 2001;15(6):637-46.
33. Jungmann EM, Mercey D, DeRuiter A, Edwards S, Donoghue S, Booth T, et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities?. Sexually transmitted infections. 2001 Dec 1;77(6):441-3.
34. Meijer WM, de Walle HE, Kerstjens-Frederikse WS, de Jong-van den Berg LT. Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists. Reprod Toxicol. 2005;20(2):203-7.

Cite this article as: Diala UM, Toma BO, Shilong D, Shwe DD, Bot G, Ofakunrin AOD, et al. Maternal and neonatal characteristics of babies admitted with congenital CNS anomalies in a tertiary hospital in North Central Nigeria. Int J Res Med Sci 2018;6:2205-9.